PlasmaTech Biopharmaceuticals, Inc. (PTBI)

2.51
0.03 1.18
NASDAQ
Prev Close 2.54
Open 2.55
Day Low/High 2.42 / 2.64
52 Wk Low/High 2.05 / 7.00
Volume 42.66K
Exchange NASDAQ
Shares Outstanding 24.27M
Market Cap 158.47M
Div & Yield N.A. (N.A)

One Reason PlasmaTech Biopharma (PTBI) Stock Is Rallying

PlasmaTech Biopharma (PTBI) stock is up after the company had coverage initiated by analysts at Roth Capital with a 'buy' rating.

PlasmaTech Biopharma (PTBI) Stock Up After Licensing Juvenile Batten Disease Treatment

PlasmaTech Biopharmaceuticals (PTBI) shares are gaining after the company announced the licensing of its juvenile Batten Disease treatment candidate.

Steady Selling Raises Level of Concern

The market has been acting differently for a while and we can't take for granted that selling pressure will end quickly.

GDP News Foils Market's Fed Surge

Keep in mind, there are no obvious signs of top forming.

The Trend Is Slow and the Mood Is Sour

It's hard to feel good about this market.

Rare Disease Drug Demand, Soros Interest Raising PlasmaTech Profile

PlasmaTech Biopharmaceuticals is enjoying a higher profile now that the business community is paying more attention to rare disease treatments, said the company's CEO Tim Miller.

PlasmaTech Biopharmaceuticals (PTBI) Stock Rises on 'Buy' Rating Coverage Initiation

PlasmaTech Biopharmaceuticals (PTBI) shares are climbing after the company had coverage initiated with a 'buy' rating and a $15 price target.

So Is This the Long-Awaited Correction?

The best thing to do is get out of the way.